Dr Conrad Savoy
Chief Scientific Officer
In 2007, Dr. Savoy was promoted to the position of Chief Scientific Officer (CSO) of Biopartners. As CSO he provides advice to the Board of Directors and the CEO on research and development strategies and their implementation, in addition to facilitating communications with Biopartners’ strategic development partners. Dr. Savoy joined Biopartners in 2001 as Head of Pharma Development where he led the Valtropin (rhGH) development through to EU market authorization. In parallel he has managed the development of the sustained-release rhGH (SR-hGH), an innovative new formulation.
Prior to joining Biopartners, Dr. Savoy spent 10 years at Hoffmann-La Roche in various senior positions, including Global Regulatory Affairs Leader. His responsibilities at Roche involved the design and implementation of development strategies for numerous novel chemical entities (NCE’s) and biopharmaceutical products during clinical development. While at Roche, Dr. Savoy gained substantial experience in dealing with global regulatory authorities, including the FDA and the EMEA, and managed several projects reliant on the centralized European approval procedure. He holds an MBA from the Open University Business School, United Kingdom, and a PhD from the University of Basel, Switzerland.
